Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 404 of 5804
-
New cocktail aims to tackle tough pancreatic cancer
Disease control Recruiting nowThe purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody therapy shows promise for rare amyloidosis
Disease control Recruiting nowThis is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly diagnosed with systemic light chain (AL) amyloidosis.
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug-radiation combo targets deadly brain tumors in early trial
Disease control OngoingThis is an open-label, multi-center Phase 0/1b study that will enroll up to 18 participants with recurrent WHO grade 4 glioblastoma (rGBM) IDH-wildtype (IDH-WT), Arm A, and 12 participants with presumed newly-diagnosed WHO grade 4 glioblastoma (nGBM) IDH-WT, Arm B. The trial will…
Phase: EARLY_PHASE1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
AstraZeneca launches human tests for bird flu vaccines
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
New strategy targets lingering lymphoma DNA in seniors
Disease control Recruiting nowOlder patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity. Identifying which patients might benefit from more therapy at the end of first-line treatment is important. The ability to me…
Phase: PHASE2 • Sponsor: Danielle Wallace • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThe purpose of this study is to determine the safety, tolerability and preliminary efficacy of NEUK203-215 , a healthy donor (HD) allogeneic CD19/BCMA-targeted CAR-NK cell product, in participants with severe, refractory autoimmune diseases. This study plans to conduct an interi…
Phase: EARLY_PHASE1 • Sponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New cell cocktail aims to prevent transplant complications in kids with leukemia
Disease control Recruiting nowTwo key methods of GVHD prevention in allogeneic HSCT have a number of limitations: ex vivo T depletion is associated with an excess of infectious complications, and pharmacological immunosuppression with insufficient efficacy of GVHD prevention. Modern graft engineering technolo…
Phase: PHASE2, PHASE3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Colonoscopy could spot Parkinson's before symptoms worsen
Diagnosis Recruiting nowThe goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease. The main question it aims to answer is: Can doctors find a protein called alpha-synuclein in colon tissue samples from…
Sponsor: CND Life Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
Supercharged immune cells take on resistant blood cancers
Disease control Recruiting nowThe goal of this clinical research study is to find the recommended safe dose of TGFBR2 KO CAR27/IL-15 NK cells that can be given to patients with relapsed/refractory disease. The safety and effectiveness of this treatment will also be studied.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Recruiting nowThis is an investigator-initiated dose-finding clinical study with the primary objective of evaluating the safety of CD5CART in the treatment of subjects with relapsed and refractory CD5 hematological malignancies and to explore the MTD of CD5CART treatment of relapsed and refrac…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New cocktail aims to tame tough pancreatic cancer
Disease control Recruiting nowThe investigators plan to initiate a prospective, multicenter, phase II study, recruiting 80 patients with advanced pancreatic cancer who have not received prior treatment. This study aims to enhance the anti-tumor immune effect through the combination of QL1706+Lenvatinib+AG reg…
Phase: PHASE2 • Sponsor: Du Juan • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Nasal spray could offer quick relief for Parkinson's 'Off' moments
Symptom relief Recruiting nowThe study is being conducted to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of XJN010 Nasal Spray in Patients with Parkinson's Disease Experiencing Off Episodes
Phase: PHASE2 • Sponsor: Guangzhou Novaken Pharm Co., Ltd. • Aim: Symptom relief
Last updated Jun 26, 2026 13:47 UTC
-
New drug combo aims to free hepatitis b patients from daily pills
Disease control OngoingThis is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients
Phase: PHASE2 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:02 UTC
-
New bone gel could help kids with rare leg fractures heal without extra surgery
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of NVD003 in pediatric participants with unilateral Congenital Pseudarthrosis of the Tibia (CPT) compared with iliac crest bone graft (ICBG) at 12 months post graft surgery.
Phase: PHASE3 • Sponsor: Novadip Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for aggressive brain cancer: experimental therapy VRT106 enters human trials
Disease control Recruiting nowThis study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug aims to stop colorectal cancer recurrence in patients with hidden tumor DNA
Disease control Recruiting nowColorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an inve…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New blood test aims to spot liver cancer recurrence early
Diagnosis Recruiting nowThrough follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined meth…
Sponsor: Wuhan Ammunition Life-tech Co., Ltd • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New inhaled therapy aims to save ventilator patients from viral pneumonia
Disease control Recruiting nowThe goal of this Phase 2 study is to assess about the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection. Its ability to speed up virus clearance and reduce mortality, …
Phase: PHASE2 • Sponsor: Synairgen Research Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental drug tarlatamab takes on rare, Tough-to-Treat cancer
Disease control Recruiting nowThis is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received platinum-based first-line chemotherapy. Participants will rece…
Phase: PHASE2 • Sponsor: Inkeun Park • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC